image dons

je fais un don

Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.

Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.

Publié dans European Heart Journal, le 01 février 2008.

En savoir plus en consultant le site.

Auteurs : Montalescot G, Cohen M, Salette G, Desmet WJ, Macaya C, Aylward PE, Steg PG, White HD, Gallo R, Steinhubl SR; STEEPLE Investigators.

Abstract

AIMS:

To determine the relationship between anticoagulation levels during percutaneous coronary intervention, and ischaemic events and bleeding.

METHODS AND RESULTS:

A sub-analysis from the STEEPLE trial was conducted. Pre-defined target anticoagulation levels were achieved in 86% of patients receiving enoxaparin, compared with 20% receiving unfractionated heparin (UFH) (P < 0.001). A significant relationship was observed between anti-Xa levels > 0.9 IU/mL and covariate-adjusted rate of non-coronary artery bypass graft-related major and minor bleeding [odds ratio (OR) 1.6, 95% CI 1.0-2.5 for each unit of anti-Xa; P = 0.03]; anti-Xa levels and covariate-adjusted incidence of death, myocardial infarction, or revascularization showed no significance (P = 0.47). Major bleeding increased significantly with an activated clotting time (ACT) > 325 s (OR 1.6, 95% CI 1.1-2.2 per 100 s; P = 0.04). A significant relationship with increasing ischaemic events was observed when ACT was < 325 s (OR 0.7, 95% CI 0.2-0.8 per 100 s; P = 0.006) indicating a narrow therapeutic window.

CONCLUSION:

Target anticoagulation levels were achieved more readily in patients receiving enoxaparin. An anti-Xa level of up to 0.9 IU/mL has a good safety and efficacy profile; poor achievement of target ACT with UFH makes assessing the optimal range difficult.

Autres actualités

+

10/09/2020


Culprit lesion location and outcomes in patients with multi-vessel disease and infarct-related cardiogenic shock. A core laboratory analysis of the CULPRIT-SHOCK trial

Publié dans EuroIntervention 2020 Sep 8: EIJ-D-20-00561. Auteurs : Hauguel-Moreau M, Barthélémy O, Farhan...
+

01/09/2020


COVID-19 acute myocarditis and Multisystem Inflammatory Syndrome in adult intensive and cardiac care units

Publié dans Chest 2020 Sep 7: S0012-3692(20)34359-2 Auteurs : Hékimian G, Kerneis M, Zeitouni M, Cohen-Au...
+

01/08/2020


Interleukin-1Beta and Risk of Premature Death in Patients with Myocardial Infarction

Publié dans Journal of the American College of Cardiology 2020 Aug 19 :S0735-1097(20)36323-3 Auteurs : Si...